Physician profile
Mohammad M Jamil
NPI 1679880025
$6,136.66
in general payments reported to CMS, 2019-2025
20 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.85 · 2020: $307 · 2021: $522 · 2022: $3,506 · 2023: $893 · 2024: $578 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Travel and Lodging: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.84 |
| Travel and Lodging | $304.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,220.14 | 2021-2024 | Mitris Resilia Mitral Valve, Inspiris Resilia Aortic Valve |
| Atricure, INC. | $1,864.45 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $729.78 | 2022-2024 | |
| Intuitive Surgical, INC. | $304.83 | 2025 | |
| Medtronic Vascular, INC. | $269.00 | 2020 | |
| Abiomed | $142.46 | 2022-2024 | Impella |
| Abbott Laboratories | $136.88 | 2023 | Portico, Octrode, Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $108.16 | 2023-2024 | Repatha |
| Medistim USA, INC. | $92.85 | 2021 | |
| Allergan, INC. | $51.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.40 | 2022-2023 | Verquvo |
| Getinge USA Sales, LLC | $25.33 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $22.92 | 2023 | Arcalyst |
| Itamar Medical INC | $22.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.88 | 2023 | Farxiga |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.80 | 2023 | |
| Daiichi Sankyo INC. | $18.60 | 2024 | Injectafer |
| Pfizer INC. | $16.51 | 2022 | |
| W. L. Gore & Associates, INC. | $14.40 | 2023 | Gore Cardioform Septal Occluder |
| Shockwave Medical, INC | $13.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.